Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®
T Brenner, R Arnon, M Sela, O Abramsky… - Journal of …, 2001 - Elsevier
Humoral and cellular immune responses were followed in multiple sclerosis patients treated
with Copolymer 1 (Cop1, glatiramer acetate, Copaxone®) who participated in three different
clinical trials. All patients (130) developed Cop1 reactive antibodies, which peaked at 3
months after initiation of treatment, decreasing at 6 months and remaining low. IgG1
antibody levels were 2–3-fold higher than those of IgG2. The proliferative response of
Peripheral Blood Mononuclear Cells (PBMC) to Cop1 was initially high and gradually …
with Copolymer 1 (Cop1, glatiramer acetate, Copaxone®) who participated in three different
clinical trials. All patients (130) developed Cop1 reactive antibodies, which peaked at 3
months after initiation of treatment, decreasing at 6 months and remaining low. IgG1
antibody levels were 2–3-fold higher than those of IgG2. The proliferative response of
Peripheral Blood Mononuclear Cells (PBMC) to Cop1 was initially high and gradually …